Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Photoselective Vaporization Prostatectomy for High-Risk Patients with Acute Urinary Retention

Photoselective Vaporization Prostatectomy for High-Risk Patients with Acute Urinary Retention To assess the clinical efficacy and safety ofphotoselective vaporization of the prostate (PVP) in thetreatment of patients with acute urinary retention, secondaryto benign prostatic hyperplasia (BPH). Patients andMethods: Thirty-two patients with acute urinary retentiondue to BPH were treated with the green-light laser, in a prospectivetrial. The treatment outcome was evaluated usingthe International Prostate Symptom Score (IPSS), diseasespecificquality of life (QoL) score, postvoiding residualurine volume and maximum urinary flow rate (Q<sub>max</sub>). Followupassessment and sexual function were performed immediatelypostoperatively and at 3, 6 and 12 months. Results:The mean patient age was 72 ± 5 years (range 65-89 years).The mean residual volume presenting with retention was350 ml (range 240-1,200ml). The mean operating time was48.6 ± 5.7 min. The mean catheterization duration after theoperation was 5.6 days (range 3-14 days). The mean IPSSand QoL decreased significantly from 22.5 ± 4.6 and 5.3 ± 1.2to 8.4 ± 5.6 (p = 0.01) and 1.8 ± 1.2 (p = 0.03), respectively.The mean residual volume decreased to 58 ml, the meanQ<sub>max</sub> was 16.2 ± 4.6 ml/s after treatment. Only 2 patients hadrecurrent urinary retention during follow-up. Conclusions: The early clinical results suggest that PVP is a promisingsafe, effective and less-invasive treatment for high-risk patientswith urine retention secondary to BPH. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Karger

Photoselective Vaporization Prostatectomy for High-Risk Patients with Acute Urinary Retention

Download PDF
4 pages

Loading next page...
 
/lp/karger/photoselective-vaporization-prostatectomy-for-high-risk-patients-with-hoT9emf0PF
Publisher
Karger
Copyright
© 2007 S. Karger AG, Basel
ISSN
1661-7649
eISSN
1661-7657
DOI
10.1159/000106526
Publisher site
See Article on Publisher Site

Abstract

To assess the clinical efficacy and safety ofphotoselective vaporization of the prostate (PVP) in thetreatment of patients with acute urinary retention, secondaryto benign prostatic hyperplasia (BPH). Patients andMethods: Thirty-two patients with acute urinary retentiondue to BPH were treated with the green-light laser, in a prospectivetrial. The treatment outcome was evaluated usingthe International Prostate Symptom Score (IPSS), diseasespecificquality of life (QoL) score, postvoiding residualurine volume and maximum urinary flow rate (Q<sub>max</sub>). Followupassessment and sexual function were performed immediatelypostoperatively and at 3, 6 and 12 months. Results:The mean patient age was 72 ± 5 years (range 65-89 years).The mean residual volume presenting with retention was350 ml (range 240-1,200ml). The mean operating time was48.6 ± 5.7 min. The mean catheterization duration after theoperation was 5.6 days (range 3-14 days). The mean IPSSand QoL decreased significantly from 22.5 ± 4.6 and 5.3 ± 1.2to 8.4 ± 5.6 (p = 0.01) and 1.8 ± 1.2 (p = 0.03), respectively.The mean residual volume decreased to 58 ml, the meanQ<sub>max</sub> was 16.2 ± 4.6 ml/s after treatment. Only 2 patients hadrecurrent urinary retention during follow-up. Conclusions: The early clinical results suggest that PVP is a promisingsafe, effective and less-invasive treatment for high-risk patientswith urine retention secondary to BPH.

Journal

Current Urology – Karger

Published: Jan 1, 2007

There are no references for this article.